close

Enter

Log in using OpenID

Amyotrophic Lateral Sclerosis (ALS) Treatment Market

embed
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market,
By Drug Type, Distribution Channel, Geography - Global
Industry Insights, Trends, Outlook, and Opportunity Analysis,
2018-2026
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron
disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord
that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse
over time.
According to a study published in Centers for Disease Control and Prevention, in 2016, around
14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases
per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and
around 15,908 people were diagnosed with ALS in 2013, according to the same study. The
increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral
sclerosis (ALS) treatment market in the near future.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1206
Approval of novel innovative drugs is expected to boost growth in amyotrophic lateral sclerosis
treatment market
In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava
(edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis
(ALS). This was the first drug to be approved after over 20 years since the last FDAapproved drug for ALS. The approval of this drug would provide an additional option
for patients suffering from this deadly disease. Increasing incidence of ALS is expected to
increase the adoption rate of this drug, in turn, boosting market growth. The drug has
already been approved in Japan and South Korea in 2015.
Report includes chapters which deeply display the following deliverable about industry :
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Objective and
Assumption
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics, Regulations, and
Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and
Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST
Analysis
• Global Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Regions
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Manufacturing Cost Analysis
including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
North America is expected to hold a dominant position in the market, increasing focus of
manufacturers on novel drug development for ALS
North America is expected to hold a dominant position in the amyotrophic lateral sclerosis
treatment market, as major companies present in the region are focusing on collaborations for
product development. For instance, in January 2018 Sangamo Therapeutics, Inc. and Pfizer Inc.
collaborated for the development of a potential gene therapy using zinc finger protein
transcription factors (ZFP-TFs) for the treatment of ALS. Companies based in emerging
economies of Asia Pacific are focusing on developing novel drugs for treatment of ALS. For
instant major companies such as Mitsubishi Tanabe Pharma Corporation and Takeda
Pharmaceutical Company Ltd are developing drugs for treatment of ALS.
Major players operating in the global amyotrophic lateral sclerosis treatment market include
Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan
Pharmaceuticals Inc.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/amyotrophic-lateral-sclerosis-treatmentmarket-1206
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy
The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug
type and distribution channel.
On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is
segmented into:
• Riluzole
• Edaravone (Radicava)
On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is
segmented into:
• Hospital Pharmacies
• Retail & Online Pharmacies
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge335   documents Email
1/--pages
Report inappropriate content